| 08:30 | P2030 | Real life heart failure, a heterogeneous population benefiting from a specialized multidisciplinary programme | Francisco ADRAGAO (Cascais, Portugal) |
|
| 08:30 | P2031 | New approaches in personalized diagnose of patients with symptomatic obstructive hypertrophic cardiomyopathy optimize the type of treatment decision-making. | Yulia FROLOVA (Moscow, Russian Federation) |
|
| 08:30 | P2033 | Reassuring community heart failure care in the absence of specialist involvement; but some gaps indicate need for continued specialist team input | Rebabonye PHARITHI (Dublin 16, Ireland) |
|
| 08:30 | P2034 | Factors influencing guideline-led prescribing to heart failure patients in an Egyptian critical care setting | Seif EL HADIDI (Cork, Ireland) |
|
| 08:30 | P2035 | Meta-analysis on MitraClip implantation for functional mitral regurgitation | Michel NOUTSIAS (Halle (Saale), Germany) |
|
| 08:30 | P2036 | First-in-human VisONE heart failure study implant experience and study design: asymptomatic diaphragmatic stimulation for chronic heart failure | Ana JORBENADZE (Tbilisi, Georgia) |
|
| 08:30 | P2037 | Heart failure patient's journey: clinical practices and attitudes regarding the diagnosis and management of heart failure | Michael BOEHM (Homburg, Germany) |
|
| 08:30 | P2038 | Service quality in a heart failure clinic: a comparison analysis to a general cardiology clinic | Luiz Claudio DANZMANN (Porto Alegre, Brazil) |
|
| 08:30 | P2040 | Consultant-led multidisciplinary community heart failure service improves the delivery of guideline directed medical therapy and reduces hospital admissions, re-admissions and length of stay. | Tahir NAZIR (Manchester, United Kingdom of Great Britain & Northern Ireland) |
|
| 08:30 | P2041 | Self-care management intervention in heart failure | Sofia GERWARD (Lund, Sweden) |
|
| 08:30 | P2042 | OPTIMIZE Heart Failure Care Program in Mexico. Impact on early and mid term Heart Failure readmissions | Jose Antonio MAGANA SERRANO (Mexico, Mexico) |
|
| 08:30 | P2043 | Overcoming challenges in adopting guideline-based device therapy in patients with heart failure; a real-world experience | Anura MALAWEERA (Croydon, United Kingdom of Great Britain & Northern Ireland) |
|
| 08:30 | P2044 | Clinical outcomes after renal replacement therapy in heart failure patients with cardiorenal syndrome and refractory congestion: a comparison between peritoneal dialysis and hemodialysis | Marcus Vinicius SIMOES (Ribeirao Preto, Brazil) |
|
| 08:30 | P2045 | Establishing the first pharmacist-led heart failure medication optimization clinic in the middle east gulf region | Ziad SADIK (Abu Dhabi, United Arab Emirates) |
|
| 08:30 | P2046 | Introduction of a multidisciplinary specialist heart failure team prevented 2 in 3 heart failure readmissions | Carla PLYMEN (London, United Kingdom of Great Britain & Northern Ireland) |
|
| 08:30 | P2047 | Current status of palliative care for heart failure; from the clinical experience of a general hospital in Japan | Yosuke NISHIHATA (Tokyo, Japan) |
|
| 08:30 | P2048 | An evaluation of heart failure register reviews and virtual clinics 2016-2018 | Gayle CAMPBELL (London, United Kingdom of Great Britain & Northern Ireland) |
|
| 08:30 | P2049 | Non-invasive Venous Waveform Analysis (NIVA) estimates static volume | Monica POLCZ (, United States of America) |
|
| 08:30 | P2050 | Vaccination uptake in HF patients; identifying a critical gap of care | Faizan RATHORE (Skerries Co Dublin, Ireland) |
|
| 08:30 | P2052 | Impact of a clinical pharmacy service on heart failure guideline-led prescribing at discharge in an Egyptian critical care unit | Margaret BERMINGHAM (Cork, Ireland) |
|
| 08:30 | P2053 | Multidisciplinary care for end-stage HF. How to improve care? | Paula FLUVIA (Girona, Spain) |
|